Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Jagsonpal Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M
Transcript · 03 Nov 2026, 10:47 pm
Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27 Earnings Conference call on October 29, 2026 at 02:00 P.M.
Audio / Video · 29 Oct 2026, 10:05 pm
Jagsonpal Pharmaceuticals Releases Audio Recording of Q2 FY27 Earnings Call Jagsonpal Pharmaceuticals has made available the audio recording of its Q2 FY27 earnings conference call held on 29th Oct'26 at 2:00 PM. The call discussed the company's unaudited financial results for the quarter, and the complete recording is accessible on the investor relations section of the company's official website.
Press Release for Unaudited Financial Results for the quarter September 30, 2026
Investor Presentation · 29 Oct 2026, 12:18 am
Jagsonpal Pharmaceuticals Reports Q2FY27 Results with 29% Consolidated Revenue Growth Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, driven by 9.3% standalone sales growth (₹814 Mn) and the consolidation of Aequitas Healthcare. Standalone EBITDA reached ₹185 Mn (22.7% margin) with PAT at ₹126 Mn. For H1FY27, standalone revenue rose 9.0% YoY to ₹1,636 Mn, while EBITDA and PAT grew 11.3% and 10.3% to ₹375 Mn and ₹258 Mn, respectively. Following an 85% stake buy in Aequitas and a 200% dividend payout, cash stood at ₹1,347 Mn as of 30th Sep'26.
Press Release for Unaudited Financial Results for the quarter ended September 30, 2026.
Press Release · 29 Oct 2026, 12:11 am
Jagsonpal Pharmaceuticals Reports Q2FY27 Results and Inorganic Expansion Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, while standalone revenue grew 9.3% YoY to ₹814 Mn with an EBITDA margin of 22.7% (₹185 Mn) and PAT of ₹126 Mn. In H1FY27, standalone revenue rose 9.0% YoY to ₹1,636 Mn and PAT rose 10.3% YoY to ₹258 Mn. Growth was aided by consolidating Aequitas Healthcare (acquired for ₹208 Mn cash) and completing the Group Pharma Wellness acquisition on 1st Oct'26, supporting the target to reach ₹5,000 Mn annual revenue by 2028.
Unaudited Financial Results (Standalone & Consolidated for the quarter and half year ended September 30, 2026.
Financial Result · 28 Oct 2026, 11:50 pm
Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 28 Oct 2026, 11:43 pm
Jagsonpal Pharmaceuticals Reports Q2 Results and Strategic Acquisitions Jagsonpal Pharmaceuticals reported standalone Q2 revenue from operations of ₹813.75m, up 9.28% YoY from ₹744.65m, with net profit rising slightly to ₹125.90m from ₹125.74m. For H1 ended 30th Sep'26, standalone revenue stood at ₹1,636.07m with net profit at ₹257.79m. Consolidated Q2 revenue reached ₹963.71m and net profit was ₹122.87m, reflecting the consolidation of newly acquired 85% stake in Aequitas Healthcare for ₹208m effective 1st Jul'26. Additionally, the company signed a BTA on 23rd Sep'26 to acquire Group Pharmaceuticals' Wellness Portfolio.
Outcome of Board Meeting held on October 28, 2026 along with Unaudited Financial Results(Standalone & Consolidated) for the quarter and half year ended September 30, 2026
Outcome · 28 Oct 2026, 11:39 pm
Jagsonpal Pharmaceuticals Reports Q2 FY27 Results and Strategic Hospital Segment Entry Jagsonpal Pharmaceuticals reported standalone revenue from operations of ₹813.75m for the quarter ended 30th Sep'26, up 9.28% YoY, with net profit at ₹125.90m versus ₹125.74m in the previous year quarter. Consolidated revenue stood at ₹963.71m with net profit at ₹122.87m. The company completed an 85% equity acquisition in Aequitas Healthcare for ₹208m effective 1st Jul'26 to enter the hospital segment, incurring ₹2.35m in exceptional deal costs. It also signed a slump sale agreement on 23rd Sep'26 to acquire Group Pharmaceuticals' Wellness Portfolio.
JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 28 Oct 2026, 5:30 am
Intimation of Analysts/Investors Conference Call
Intimation · 29 Oct 2026, 2:00 pm
Jagsonpal Pharmaceuticals Schedules Q2 and H1 FY27 Earnings Call Jagsonpal Pharmaceuticals Limited will host an earnings conference call for analysts and investors on 29th Oct'26 at 2:00 PM IST to discuss its financial performance for Q2 and H1 FY27. Key management participants include Managing Director Manish Gupta, Chief Operating Officer Amrut Medhekar, and Chief Financial Officer Nirav Vora. The call is hosted by Go India Advisors, with universal dial-in access available via +91 22 6280 1557 and +91 22 7115 8383 alongside pre-registration Diamond Pass options.
Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Financial ....
Intimation · 28 Oct 2026, 5:30 am
Jagsonpal Pharmaceuticals Schedules Board Meeting for Q2 Earnings on 28th Oct'26 Jagsonpal Pharmaceuticals Limited has scheduled a meeting of its Board of Directors on 28th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter ended 30th Sep'26. Additionally, the company's trading window for dealing in its securities will remain closed until 30th Oct'26, in continuation of its prior intimation dated 25th Sep'26.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 28 Oct 2026, 5:30 am
Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated with effect from today i.e. October 01, 2026.
Others (Uncategorized) · 01 Oct 2026, 10:27 pm
Jagsonpal Completes Group Pharma Wellness Portfolio Acquisition Jagsonpal Pharmaceuticals consummated the acquisition of Group Pharmaceuticals' Wellness Portfolio on 1st Oct'26. The deal comprises an upfront consideration of ~₹23.7 Cr and maximum performance-linked deferred consideration of ~₹23.0 Cr tied to FY28 sales. The acquired business generated ~₹24.6 Cr revenue in FY26 with a ~78.0% gross margin across 6 states, led by brands Hemozink and Sudin. Supported by a ~₹170 Cr cash balance as of Q1FY27, this margin-accretive transaction advances Jagsonpal's inorganic strategy toward its ₹500 Cr revenue target by FY28.
Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022
Others (Uncategorized) · 30 Sept 2026, 9:38 pm
Jagsonpal Pharmaceuticals Allots 101825 Equity Shares Under JPL ESOP 2022 Jagsonpal Pharmaceuticals Limited has allotted 1,01,825 equity shares of face value Rs. 2 each on 30th Sep'26 following the exercise of vested options under the JPL ESOP 2022. The allotment comprises 1,00,000 shares exercised at Rs. 94.00 per share and 1,825 shares at Rs. 115.60 per share. Consequently, the company's paid-up equity capital increased from Rs. 13,19,14,840 (6,59,57,420 shares) to Rs. 13,21,18,490 (6,60,59,245 shares). The newly issued shares rank pari-passu with existing equity shares.
Press Release on Acquisition of Wellness Portfolio of Group pharmaceuticals Limited
Press Release · 23 Sept 2026, 11:32 pm
Jagsonpal Pharmaceuticals Acquires Group Pharma’s Wellness Portfolio for up to ₹46.7 Crores Jagsonpal Pharmaceuticals executed a Business Transfer Agreement on 23rd Sep'26 to acquire the Wellness Portfolio of Group Pharmaceuticals via slump sale. The target portfolio generated ₹24.6 crore turnover in FY'26 and strengthens Jagsonpal’s footprint in women’s healthcare. The transaction includes an initial cash consideration of ₹23.7 crore at closing, with performance-linked consideration of up to ₹23.0 crore tied to FY'28 sales, capping total payout at ₹46.7 crore. The acquisition requires no regulatory approvals and is slated for completion on or before 1st Nov'26.
Acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited.
Others (Uncategorized) · 23 Sept 2026, 11:22 pm
Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio for up to ₹46.7 Crores Jagsonpal Pharmaceuticals signed a Business Transfer Agreement on 23rd Sep'26 to acquire the Wellness Portfolio of Group Pharmaceuticals via a slump sale on a going-concern basis. The target portfolio generated ₹24.6 crore in FY26 turnover. Total consideration is capped at ₹46.7 crore, comprising an upfront cash payment of ₹23.7 crore at closing and up to ₹23.0 crore in performance-linked earnouts tied to FY28 sales. The deal expands Jagsonpal’s footprint in women’s healthcare and is expected to close on or before 1st Nov'26.
Voting Result and scrutinizer Report of 47th Annual General Meeting.
Annual General Meeting · 21 Sept 2026, 10:35 pm
Summary of Proceedings of 47th Annual General Meeting.
Annual General Meeting · 18 Sept 2026, 10:41 pm
Notice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-26
Annual General Meeting · 28 Aug 2026, 1:48 am
BRSR for the Financial year ended March 31, 2026
Others (Uncategorized) · 28 Aug 2026, 1:36 am
Jagsonpal Pharmaceuticals FY26 BRSR Highlights Key Operating and ESG Metrics Jagsonpal Pharmaceuticals' BRSR for FY26 highlights key operational metrics. Pharmaceutical formulations contributed 99.42% to turnover, with exports to Bangladesh and Malaysia at 0.09%. The permanent employee turnover rate increased to 58% in FY26 from 52% in FY25. Accounts payable days extended to 40 days from 37 days in the prior year. CSR beneficiaries for the year reached 9,576 people. No fines, penalties, or product recalls were reported. The company maintains its focus on marketing and distribution, outsourcing 100% of its manufacturing.
Annual report for Financial Year 2025-26
Others (Uncategorized) · 28 Aug 2026, 1:21 am
Letter providing a web link of annual report 2025-26 to members.
Annual Report · 27 Aug 2026, 11:09 pm
Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022
Others (Uncategorized) · 24 Aug 2026, 5:23 pm
Jagsonpal Pharma Allots ESOP Shares, Leading to Minor Equity Dilution On 24 Aug'26, Jagsonpal Pharmaceuticals allotted 27,950 new equity shares of Rs. 2 par value under its "JPL ESOP 2022" scheme. The shares were issued upon the exercise of vested options at prices ranging from Rs. 94.00 to Rs. 115.60 per share. This allotment increases the company's paid-up share capital from Rs. 13.186 cr to Rs. 13.191 cr, and the total number of equity shares rises to 6,59,57,420. The new shares rank pari-passu with existing equity, resulting in minor equity dilution.
Earning Call Transcript for meeting held on July 30, 2026
Transcript · 04 Aug 2026, 9:49 pm
Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30, 2026 at 2:30 P.M.
Audio / Video · 30 Jul 2026, 11:00 pm
Jagsonpal Pharma Uploads Q1 FY27 Earnings Call Recording Jagsonpal Pharmaceuticals announced the availability of the audio recording for its Q1 FY27 earnings conference call. The call, held on Jul 30, 2026, discussed the company's financial results for the quarter ended Jun 30, 2026. As per SEBI regulations, the recording has been uploaded to the investor relations section of the company's website. This filing provides access for investors and analysts to review management's discussion and outlook.
Change in Senior Management personnel of the Company
Change in Management · 30 Jul 2026, 12:15 am
Jagsonpal Pharma Designates Two New Senior Management Personnel Jagsonpal Pharmaceuticals (JAGSNPHARM) designated two individuals as Senior Management Personnel effective 29 Jul'26, following an internal restructuring. Mr. Balmukund Keshav, with 29 years of IT experience, was named Deputy General Manager (Information Technology). Mr. Sanjay Singhal, a pharmacy professional with 31 years of industry experience, was appointed General Manager (CQA & Regulatory Affairs). Both appointments are internal designations and not new hires, with Keshav having a 17-year tenure at the company and Singhal joining in Mar'20.